^
    19d
    A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Shandong Suncadia Medicine Co., Ltd.
    New P3 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib) • Airuikai (glecirasib) • Dupert (fulzerasib)
    3ms
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=140, Active, not recruiting, InxMed (Shanghai) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib) • ifebemtinib (IN10018)
    3ms
    Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) (clinicaltrials.gov)
    P2, N=32, Not yet recruiting, Guangdong Provincial People's Hospital
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    carboplatin • paclitaxel • Anfangning (garsorasib) • Idafang (ivonescimab)
    5ms
    a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors (clinicaltrials.gov)
    P1/2, N=140, Recruiting, InxMed (Shanghai) Co., Ltd. | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib) • ifebemtinib (IN10018)
    5ms
    A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (clinicaltrials.gov)
    P3, N=400, Recruiting, InxMed (Shanghai) Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    cisplatin • carboplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed • Anfangning (garsorasib) • ifebemtinib (IN10018)
    5ms
    Phase 2 Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GH21 Capsules Combined With D-1553 Tablets in Subjects With Locally Advanced or Metastatic Solid Tumors With the KRASG12C Mutation (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Suzhou Genhouse Bio Co., Ltd.
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib) • HBI-2376
    6ms
    Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC (clinicaltrials.gov)
    P2, N=69, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Erbitux (cetuximab) • Focus V (anlotinib) • Andewei (benmelstobart) • Anfangning (garsorasib)
    6ms
    Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. (PubMed, Br J Cancer)
    Garsorasib demonstrated encouraging antitumor activity and a tolerable safety profile in patients with KRAS G12C-mutated advanced pancreatic cancer.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib)
    6ms
    Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study. (PubMed, Eur J Cancer)
    This pooled analysis confirmed the robust efficacy and manageable safety of garsorasib in KRAS G12C-mutated NSCLC.
    P1/2 data • Retrospective data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Anfangning (garsorasib)
    7ms
    Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors. (PubMed, Front Oncol)
    In this report, we present two patients with advanced PDAC with KRAS G12C mutations who achieved remarkable disease control and prolonged survival following treatment with the KRAS G12C inhibitor D1553 (garsorasib)...Case 2, a 75-year-old woman initially treated with Folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) and stereotactic body radiotherapy (SBRT), demonstrated sustained disease stability for over three years on KRAS G12C inhibitor therapy...These cases underscore the potential of KRAS-directed therapies in PDAC and illustrate the importance of molecular profiling in identifying eligible patients. The findings support further investigation into the durability of KRAS G12C inhibition, resistance mechanisms, and combination treatment strategies to optimize patient outcomes.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Anfangning (garsorasib)
    7ms
    Galaxy-L-01: A Multicenter, Prospective Clinical Study Evaluating the Garsorasib Plus Anlotinib as First-Line Therapy for KRAS G12C-Mutant Advanced Non-Squamous NSCLC (ChiCTR2500110453)
    P4, N=104, Not yet recruiting, Shanghai Chest Hospital; Shanghai Chest Hospital
    New P4 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    cisplatin • carboplatin • Focus V (anlotinib) • pemetrexed • Anfangning (garsorasib)
    7ms
    Phase II study of Garsorasib for the adjuvant treatment of KRAS G12C-mutated NSCLC (ChiCTR2500107544)
    P2, N=30, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
    |
    PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Anfangning (garsorasib)